January 2017 - Volume 23 - Issue 1 - Contributor Index

Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers

Herfarth, Hans H.; Jackson, Susan; Schliebe, Barbara G.; More

Inflammatory Bowel Diseases . 23(1):14-22, January 2017.

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

Sands, Bruce E.; Sandborn, William J.; Van Assche, Gert; More

Inflammatory Bowel Diseases . 23(1):97-106, January 2017.

Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease

Roblin, Xavier; Duru, Gerard; Williet, Nicolas; More

Inflammatory Bowel Diseases . 23(1):126-132, January 2017.

Inflammation and Apoptosis: Dual Mediator Role for Toll-like Receptor 4 in the Development of Necrotizing Enterocolitis

Zhou, Yin; Li, Yibo; Zhou, Bin; More

Inflammatory Bowel Diseases . 23(1):44-56, January 2017.

Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease

Van Der Sloot, Kimberley W. J.; Joshi, Amit D.; Bellavance, Danielle R.; More

Inflammatory Bowel Diseases . 23(1):82-88, January 2017.